ere Breast Cancer Recurrence · Breast Cancer Symposium. Abstract S5-04. Presented December 11,...
2
Fear of recurrence is something that almost every person who has been diagnosed with breast cancer faces. This Recurrence Discussion Guide aims to make it easier for you to talk openly with your healthcare team about this fear and how you can manage it. Taking an active role in your treatment planning can help you feel more confident that you’re doing everything you can to reduce the risk of your breast cancer recurring. First, it may help to think about the topics or concerns that are most important to you right now, so that you can share them with your doctor or nurse. These could include questions to help you better understand your disease, any treatment information that is confusing, or next steps. 1. 2. 3. Next, below are some common, specific questions that you may want to ask your healthcare team to learn more about your HER2+ breast cancer and the risk that it will recur. If you know someone with HER2+ breast cancer, this Recurrence Discussion Guide can be a useful tool to help both of you have increased confidence in the management of your loved one’s cancer. Let’s Talk About HER2+ Breast Cancer Recurrence I know that I have HER2+ breast cancer. What is my hormone receptor status, and can you explain what it means? I know that HER2+ breast cancer returns in about 1 in 4 women after adjuvant treatment (following surgery) with Herceptin ® (trastuzumab). 1-5 Given my age, cancer stage, hormone receptor status, lymph node involvement and response to prior therapies (as applicable), what is the risk that my breast cancer will recur? What changes should we consider making to my treatment plan to help reduce the risk that my cancer will recur? Are there lifestyle changes I can make to reduce the risk of my cancer returning? What additional medications can I take to help reduce the risk that my HER2+ breast cancer will recur? Important Questions for Your Healthcare Team About Recurrence Print this guide and bring it to your next scheduled appointment to help you start the conversation. Recurrence is serious because it can mean progression to metastatic disease (cancer that has spread to other parts of the body), so understanding the steps you can take to help reduce your risk of recurrence is important.
Transcript of ere Breast Cancer Recurrence · Breast Cancer Symposium. Abstract S5-04. Presented December 11,...
website addressdownload
UNDERSTANDING HER2+ BREAST CANCER RECURRENCE
Fear of recurrence is something that almost every person who has been diagnosed with breast cancer faces. This Recurrence Discussion Guide aims to make it easier for you to talk openly with your healthcare team about this fear and how you can manage it. Taking an active role in your treatment planning can help you feel more confident that you’re doing everything you can to reduce the risk of your breast cancer recurring.
First, it may help to think about the topics or concerns that are most important to you right now, so that you can share them with your doctor or nurse. These could include questions to help you better understand your disease, any treatment
information that is confusing, or next steps.
1.
2.
3.
Next, below are some common, specific questions that you may want to ask your healthcare team to learn more about your HER2+ breast cancer and the risk that it will recur.
ReduceRecurrence.com
RecurrenceDiscussion Guide
download
B
REAST C
AN
CER
HER2+
If you know someone with HER2+ breast cancer, this
Recurrence Discussion Guide can be a useful tool
to help both of you have increased confidence in
the management of your loved one’s cancer.
ReduceRecurrence.com
RecurrenceDiscussion Guide
download
BREAST C
AN
CER
HER2+
Let’s Talk About HER2+ Breast Cancer Recurrence
I know that I have HER2+ breast cancer. What is my hormone receptor status, and can you explain what it means?
I know that HER2+ breast cancer returns in about 1 in 4 women after adjuvant treatment (following surgery) with Herceptin® (trastuzumab).1-5 Given my age, cancer stage, hormone receptor status, lymph node involvement and response to prior therapies (as applicable), what is the risk that my breast cancer will recur?
What changes should we consider making to my treatment plan to help reduce the risk that my cancer will recur?
Are there lifestyle changes I can make to reduce the risk of my cancer returning?
What additional medications can I take to help reduce the risk that my HER2+ breast cancer will recur?
Important Questions for Your Healthcare Team About Recurrence
Print this guide and bring it to your next scheduled appointment to help you start the conversation.
Recurrence is serious because it can mean progression to metastatic disease (cancer that has spread to other parts of the body), so understanding the steps you can take to help reduce your risk of recurrence is important.
Herceptin is a registered trademark of Genentech, Inc.References:1. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:1-10. 2. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34): 5685-5692. 3. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open label, randomised controlled trial. Lancet. 2013;382:1021-1028. 4. Slamon DJ, Eiermann W, Robert NJ, et al. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04. Presented December 11, 2015. 5. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205
©2017 Puma Biotechnology, Inc. All Rights Reserved. PRC-US-NER-0247 10/17
How Can I Learn More?In addition to your healthcare team, there are other trusted resources within the breast cancer community that you can rely on for information and support.
Visit ReduceRecurrence.com for several that you may find helpful.
Tips for Discussions With Your Healthcare TeamWrite down your list of questions and concerns before your appointment and bring them with you
Have a notebook on hand or use a recording device to take notes
Share your questions and concerns with a friend or family member and, if possible, have him or her join you at your appointment to help communicate these questions to your healthcare team
Don’t be afraid to tell your healthcare team if you don’t understand something – it’s important to ask questions so that you feel confident in the information you are provided
If you need more time to talk but your doctor isn’t available, ask to speak to another member of your healthcare team, such as a nurse
Ask for the doctor’s or healthcare team’s contact information and their preferred method of communication
ReduceRecurrence.com
RecurrenceDiscussion Guide
download
BREAST CA
NC
ER
HER2+Get the Facts, and Act to Reduce Your Risk
Visit ReduceRecurrence.comfor more information
